CSTL CASTLE BIOSCIENCES INC Insider Trading

COO Oelschlager sells 14,888 shares of CSTL at $39.31; retains 12,323 post-sale. Stock up 13.8% in 30d, 61.6% in 90d.

Oelschlager Kristen M, Chief Operating Officer of Castle Biosciences, sold 14,888 shares at $39.31 on 2025-12-17, reducing her holdings by 54.7% from 27,211 to 12,323 shares. The sale occurred when the stock was trading -1.3% from its 52-week high of $39.95, near a recent peak. Castle Biosciences has shown strong 30-day (+13.8%) and 90-day (+61.6%) price appreciation, and the company reports 51.1% annual revenue growth on $83.0M quarterly revenue, despite a -$501.0K net loss. The timing of this substantial reduction in executive holdings, at near-peak valuations and following sustained momentum, warrants monitoring of the company's forward guidance and operational trajectory.

CEO Derek Maetzold sold 32,346 shares (48.1% of holdings) across 3 transactions for $1,251,399.69

Derek Maetzold, President & Chief Executive Officer of Castle Biosciences, executed 3 separate sales totaling 32,346 shares for $1,251,399.69 on December 15–16, 2025, at prices ranging from $38.55 to $39.30. This disposition reduced his holdings from 67,215 shares to 34,869 shares, representing a 48.1% reduction in his post-transaction holdings. The sale occurred within the stock's 52-week range ($14.65–$39.95) and near its 52-week high of $39.95 (-0.7%), following a pronounced rally: 90-day change of +69.0% and 30-day change of +16.8%. The company's fundamentals show strong revenue growth (+51.1% year-over-year, with latest quarterly revenue of $83,043,000.00) but current losses (net income of $-501,000.00), and an elevated valuation multiple (P/E of 60.09). The magnitude of the reduction and the proximity to 52-week highs warrant investor review of the company's forward guidance and competitive positioning.

COO Oelschlager sells 18,932 shares of CSTL for $664.5K, reducing holdings by 60.6% on day stock trades 52.6% above 30-day average.

Oelschlager Kristen M, Chief Operating Officer, sold 18,932 shares at $35.10 on 2025-11-11, reducing her stake from 31,255 to 12,323 shares—a 60.6% reduction in holdings. The sale occurred while CSTL traded near its 52-week high of $34.97, with the stock up 52.6% over the prior 30 days and 69.8% over 90 days, suggesting the sale captured significant recent momentum. The company shows strong annual revenue growth of 51.1% to $83.0M but is unprofitable (net income of $-501.0K in the latest quarter), trading at a P/E of 51.70 with a market cap of $995.9M—valuation metrics that may reflect the market's growth expectations rather than current earnings power. The substantial sale, executed at a favorable price point after an extended rally, warrants examination of whether execution or strategic positioning drove the decision.